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Introduction: The main therapeutic approach to a Masaoka stage III
thymic epithelial neoplasm (TEN) is surgical resection, and the
5-year survival rate is approximately 60%. According to the
Masaoka staging system, invasion of neighboring organs is classi-
fied as stage III disease, regardless of the number of organs involved
or the size of the tumor. We retrospectively analyzed the prognostic
significance associated with the extent of disease in patients with
Masaoka stage III TENs.
Methods: From 1995 to 2006, 241 patients were identified with
thymomas. Among these patients, 59 were diagnosed with Masaoka
stage III disease. The patients with a stage III TEN were advised to
have extended thymectomy with en bloc resection of the invaded
structures as the initial treatment. The prognostic significance of the
size, organs invaded, and other factors were analyzed.
Results: The overall survival rates for the stage III patients were 83%
and 64%, and the recurrence-free survival rates were 56% and 51%, at
5 and 8 years, respectively. Patients with a low-grade World Health
Organization classification (p  0.0202) or a complete resection (p 
0.0001) had a better overall survival. In addition, patients with tumors
less than 6.5 cm (p  0.0311) or with pericardium invasion (p 
0.0299) had a better recurrence-free survival. The patients with limited
disease had a better prognosis for a recurrence-free survival than did
patients with extensive disease (p  0.0007).
Conclusions: Heterogeneous prognostic subgroups based on tumor
size and organs invaded were identified in patients with Masaoka
stage III TENs. Therapeutic plans, based on these subgroups, will
potentially improve patient management and treatment outcomes.
Key Words: Thymoma, Surgery, Thymectomy, Statistics, Survival
analysis.
(J Thorac Oncol. 2009;4: 1561–1567)
Thymic epithelial neoplasm (TEN), the most commontumor of the anterior mediastinum, are epithelial neo-
plasms of the thymus that have a wide spectrum of morpho-
logic features.1–3 The most widely adopted staging system is
the one proposed by Masaoka et al.4 in 1981, which is based
on local extension (invasiveness) of the tumor; it has been
shown to be associated with the prognosis of patients with
thymomas. Surgery for Masaoka stages I and II disease has
resulted in a 5-year survival rate of 95 to 99% and 80 to 85%,
respectively. However, the 5-year survival rate for stage III
disease is approximately 60%; this survival rate has not
changed over the past 3 decades.5–12
According to the Masaoka staging system,4 disease that
invades neighboring organs such as the pericardium, lungs,
great vessels, or other surrounding organs, without pleural
dissemination and distant metastases, are all classified as
stage III disease, regardless of the size of the tumor or the
number of organs invaded. There have been several studies
focusing on the prognostic significance of great vessel inva-
sion and the completeness of surgical resections8,13–15; how-
ever, the significance of each organ invaded, the tumor size,
the World Health Organization (WHO) classification, and
adjuvant therapy remains to be elucidated.
In this study, we retrospectively analyzed the prognostic
heterogeneity of patients with stage III TENs that underwent
surgical treatment at a single hospital over a period of 12 years.
PATIENTS AND METHODS
Patients
Our institutional review board approved this study and
waived the requirement for individual patient consent (insti-
tutional review board no. 2008-02-018). From 1995 to 2006,
241 patients had pathologically confirmed TENs at our institu-
tion. All patients were evaluated with computed tomography for
the determination of complete surgical respectability before
surgical treatment. The stages were classified according to the
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Masaoka staging system, which was originally described based
on the surgical stage. One pathologist (with more than 15 years
of experience, J.H.) classified the histologic types of TEN
according to the WHO classification; all cases diagnosed
before 1999 were reclassified according to the WHO clas-
sification.16 The mean age at diagnosis was 54 years
(range, 23–77 years). Thirty-four patients (58%) were
male. Five patients (8%) had myasthenia gravis. The
patient characteristics including WHO classification and
the details of invasion of the surrounding organs are shown
in Table 1.
Treatment
Surgery was recommended as the initial treatment for
patients with stage III TEN who were candidates for complete
resection based on the preoperative evaluation. An extended
thymectomy, with en bloc resection of invaded structures,
was planned for complete resection of the stage III patients.
In two cases (3%), an extensive operation was performed with a
posterolateral thoracotomy for a TEN invading the lungs, pleura,
or both. Extension of the surgery was required to the lungs in 44
cases (73%, 41 wedge resections, four lobectomies), the peri-
cardium in 31 cases (52%), the great vessels in 13 cases (22%,
10 innominate vein resections with/without reconstructions,
four superior vena cava resection with reconstructions), the
mediastinal pleura, the phrenic nerve in three cases (5%), and
the chest wall in one case (2%).
Forty-three patients (73%) underwent a complete resec-
tion with negative microscopic margins (R0). Thirteen pa-
tients (22%) had a complete resection planned but were not
resected completely based on microscopic examination (R1).
In three patients, a complete resection could not be performed
because there was extensive disease with multiple organs
invaded by the tumor. There were five cases with postoper-
ative complications: two pneumonias, one wound dehiscence,
one chylothorax, and one arrhythmia; however, the compli-
cations were not life threatening.
All stage III TEN patients were recommended postop-
erative adjuvant radiotherapy. Postoperative adjuvant radia-
tion therapy for the anterior mediastinum was given to the
patients with Masaoka stage III TENs with a 6 to 10 MV
linear accelerator. The radiation therapy was started 4 to 6
weeks after surgery, and the total dose was 54 Gy. In cases of
postoperative combined chemotherapy and radiotherapy, ra-
TABLE 1. Patient Characteristics




Presence of myasthenia gravis 5 (8%)









Lung only 17 (29%)
Lung  pericardium 20 (34%)
Lung  great vessel 3 (5%)
Lung  great vessel  pericardium 1 (2%)
Lung  great vessel  parietal pleura including
phrenic nerve
1 (2%)
Lung  great vessel  pericardium  parietal
pleura including phrenic nerve
1 (2%)
Pericardium only 8 (14%)
Great vessel only 5 (8%)
Great vessel  pericardium 1 (2%)
Great vessel  chest wall 1 (2%)





Adjuvant therapy 44 (75%)
RTx only 36 (61%)
CRTx 8 (14%)
WHO, World Health Organization; R0, complete resection with negative micro-
scopic margins; R1, incomplete resection on microscopic examination; R2, macroscop-
ically incomplete resection; RTx, radiation therapy; CRTx, chemoradiation therapy.
TABLE 2. The Invaded Organs According to the WHO
Classification
WHO Classification Invaded Organs
A Lung only 3 (5%)
AB Lung only 2 (3%)
B1 Lung  pericardium 1 (2%)
B2 Lung only 2 (3%)
Lung  pericardium 2 (3%)
Lung  great vessel 2 (3%)
Lung  great vessel  pericardium 1 (2%)
Pericardium only 3 (5%)
Great vessel only 1 (2%)
Parietal pleura including phrenic
nerve
1 (2%)
B3 Lung only 5 (8%)
Lung  pericardium 10 (17%)
Pericardium only 1 (2%)
Great vessel only 1 (2%)
Great vessel  pericardium 1 (2%)
C Lung only 5 (8%)
Lung  pericardium 7 (12%)
Lung  great vessel 1 (2%)
Lung  great vessel  parietal pleura
including phrenic nerve
1 (2%)
Lung  great vessel  paricardium 
parietal pleura including phrenic
nerve
1 (2%)
Pericardium only 4 (7%)
Great vessel only 3 (5%)
Great vessel  chest wall 1 (2%)
WHO, World Health Organization.
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diotherapy was administered first and then followed by three
cycles of a cyclophosphamide chemotherapy regimen.17 After
the surgery, patients were monitored every 3 to 4 months with
chest computed tomography scans for 2 years, every 6 months
for 3 years and yearly thereafter.
Pathology
Immunohistochemical staining was used to distinguish
TEN from other mediastinal tumors, using 1:50 CD5 (DAKO,
Carpinteria, CA), 1:100 cytokeratin (DAKO), 1:50 MIC-2
(CD99) (DAKO), 1:100 leukocyte common antigen (DAKO),
and 1:40 placental leukocyte alkaline phosphatase (Novocastra,
Newcastle upon Tyne, UK). The distribution of tumor types
was as follows: A-3 (5%), AB-2 (3%), B1-1 (2%), B2-13
(22%), B3-18 (30%), and C-23 (38%). The invaded organs,
according to WHO classification, are shown in Table 2.
Evaluation of the Prognostic Factors
The following variables were considered as possible
prognostic factors: age, gender, presence of myasthenia gra-
vis, tumor size, WHO classification, invaded organ, complete
resection, and adjuvant therapy.
The overall survival was calculated from the time of the
histologic diagnosis to the last follow-up date or death of any
cause; the follow-up of patients who died was complete at the
time of their death. The recurrence-free survival was calcu-
lated from the time of diagnosis to the last follow-up date or
recurrence. The mean follow-up was 42 months and ranged
from 2 to 103 months. One patient was lost to follow-up at 29
months after surgery.
The Kaplan-Meier estimator was used to construct the
survival curves. Comparisons by prognostic factors between
the two curves were performed using the log-rank test. All
p values are two tailed. The prognostic factors were identified
by the multiple Cox proportional hazards regression method.
The Cochran-Mantel-Haenszel test was used to compare the
WHO classification differences between a limited disease
group and an extensive disease group. A p value less than
0.05 was considered significant unless otherwise stated (the
definition of limited and extensive disease are given in the
Results section).
RESULTS
The overall survival rates for 59 stage III patients were
83% at 5 years and 64% at 8 years; the recurrence-free
survival rates were 56% at 5 years and 51% at 8 years (Figure
1). There were 19 cases with tumor recurrence (34%). Most
of them were local (84%); in one case, there were multiple
lumbar spine metastases, and in two cases, there were ex-
FIGURE 1. Kaplan-Meier curves of overall survival and recurrence-free survival with confidence intervals (dotted line) of pa-
tients with Masaoka stage III thymomas (n  59).
TABLE 3. The Results of the Univariate Analysis of Overall











Size (cm) 6.5:6.5 0.4627 0.0311




Invaded organs Pericardium 0.5095 0.0299










Adjuvant therapy 0.1524 0.7992
WHO, World Health Organization.
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trathoracic lymph node metastases. Of those, six patients
were treated by radiotherapy combined with chemotherapy
(adriamycin, cisplatin, and cyclophosphamide), six patients
were radiotherapy alone, four patients were chemotherapy
alone, two patients refused additional treatment, and one
patient was transfer out. Eleven patients died of treatment-
related deaths (adverse effects from radiotherapy or chemo-
therapy such as severe radiation pneumonitis or neutropenia).
The univariate analysis of overall survival showed that the
patients with a low-grade WHO classification (p 0.0202) or
those with a complete resection (p  0.0001) had better out-
comes (Table 3 and Figure 2). For the multivariate analysis, the
WHO classification and a complete resection were also signifi-
cantly associated with the overall survival (Table 4).
The size of the tumors ranged from 2 to 14 cm, and the
median was 6.5 cm. Therefore, we used 6.5 cm as a cutoff value.
The univariate analysis of recurrence-free survival showed that
a tumor size of less than 6.5 cm (p  0.0311) was associated
with better patient outcome. A low-grade WHO classification,
with single organ invasion and pericardium invasion were
associated with better outcomes (p  0.0518, 0.0181, and
0.0299) (Table 3 and Figure 3). However, in contrast to the
factors associated with overall survival, only the low grade
WHO classification was significant in the multivariate anal-
ysis (Table 4).
Our results showed that the completeness of the surgical
resection was one of the most significant prognostic factors. This
finding is consistent with previous reports. We further analyzed
the patients with completely resected stage III TENs (n  43).
We divided 43 patients according to the tumor size and the
number of organs invaded, which were significant features in
the univariate analysis. A group with limited disease (group
A, n  29) was defined as the patients with a TEN: (1) that
invaded only one organ or (2) invaded two organs, and the
FIGURE 2. Kaplan-Meier curve of overall survival by the WHO classification (A), completeness of resection (B). R0: complete
resection with negative microscopic margins; R1: incomplete resection on microscopic examination (R1); and R2: macroscopi-
cally incomplete resection.
TABLE 4. The Results of the Multiple Regression Analysis of Overall Survival and Recurrence-Free
Survival
Overall Survival Recurrence-Free Survival
p Hazard Ratio p Hazard Ratio
Sex NS 0.49 (0.12–2.04) NS 0.86 (0.33–2.25)
Age NS 1.01 (0.95–1.08) NS 1.01 (0.97–1.06)
Presence of myasthenia gravis NS 0 NS 0
Size NS 0.90 (0.62–1.31) NS 1.04 (0.84–1.29)
WHO classification 0.0353 4.77 (1.11–20.47) 0.0278 1.89 (1.07–3.35)
No. of invaded organs NS 0.76 (0.33–1.76) NS 1.03 (0.07–16.29)
Invaded organs
Lung NS 0.48 (0.08–3.05) NS 1.25 (0.03–62.15)
Great vessel NS 0.17 (0.01–2.51) NS 0.84 (0.01–83.72)
Pericardium NS 1.86 (0.36–9.64) NS 2.03 (0.08–49.71)
Completeness of resection 0.0038 14.31 (2.12–96.47) NS 2.28 (0.74–7.04)
Adjuvant therapy NS 0 NS 0.35 (0.08–1.60)
WHO, World Health Organization; NS, not significant.
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tumor was less than 6.5 cm in diameter. A group with
extensive disease (group B, n  14) was defined as those
patients with tumors: (1) that invaded two organs and had a
tumor 6.5 cm or larger in diameter or (2) invaded three or
more organs. There was no significant difference in the
distribution of the WHO classification between the two
groups (p  0.7721). In the survival analysis, using the
Kaplan-Meier estimator, the overall survival analysis did not
show a statistically significant difference between the two
groups. However, the recurrence-free survival analysis
showed a better outcome in the limited disease group com-
pared with the extensive disease group (p  0.0007). These
findings were also observed in the patients with a complete
macroscopic surgical resection (R0  R1, n  56, p 
0.0001). The overall survival and recurrence-free survival
curves for the limited and extensive disease groups are shown
in Figures 4A, B.
DISCUSSION
Surgery is the primary therapy for epithelial tumors of
the thymus. For stage III TENs, the outcomes are different for
stage I and II disease. Even with a complete resection, the
outcomes of patients with stage III TENs are unsatisfactory.
The 10-year survival rate of patients with stage III TENs has
been reported to be 26 to 78%.5–12 Our findings are consistent
with prior reports; in this study, the overall survival rates
were 83% at 5 years and 64% at 8 years, and the recurrence-
free survival rates were 56% at 5 years and 51% at 8 years.
By definition, small TEN have limited invasion into the
pericardium, they are considered stage III disease and can be
resected easily with a likely favorable prognosis. However, large
tumors with extended invasion into multiple organs, including
the great vessels, are also considered stage III disease. The
Masaoka staging system, especially for stage III TENs, does not
always accurately reflect patient prognosis.18,19
In our study of Masaoka stage III TENs, the WHO
classification and the completeness of the surgical resection
were significant factors associated with the overall survival in
both the univariate and multivariate analyses. In addition, for
the recurrence-free survival analysis, the WHO classification
was significant in the univariate and multivariate analyses.
These findings are consistent with many prior reports on
thymomas.5,7,8,10,12–15,17,20,21 The size of the tumor appears to
be associated with survival. When the size of the TEN was
FIGURE 3. Kaplan-Meier curve of recurrence-free survival by size (A), WHO classification (B), number of organs invaded (C),
and pericardium invasion (D).
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less than 6.5 cm, patients had a better prognosis for recur-
rence-free survival. Other groups have reported similar re-
sults.5,14,22 Nevertheless, the size criteria and outcomes have
been inconsistent. Blumberg et al.5 reported that thymomas over
11 cm had a significantly reduced survival. Wright et al.14 also
reported that thymomas 8 cm or more had a significantly
worse prognosis. In the report by Nakagawa et al.,22
thymomas more than 10 cm were associated with a poor
prognosis. Therefore, even though the sizes are not all the
same, most studies, including ours, show that larger TEN
are associated with an unfavorable outcome compared with
smaller TEN.
The prognosis of stage III TENs has not been fully
evaluated. In our study of patients with stage III TEN,
assessment of the prognosis by the number of organs invaded
showed that there was a better prognosis with single organ
invasion than with more than two organs invaded. This
finding is consistent with the report of Asamura et al.,18 who
investigated the survival of patients with thymomas accord-
ing to the number of organs involved. Invasion of specific
organs showed that there was a better prognosis, in patients
with invasion of the pericardium than invasion of other
organs, for the recurrence-free survival by univariate anal-
ysis (p  0.0299). Previous reports on the prognostic
significance of the invaded organs focused primarily on the
great vessels. Among these reports, only the report by
Okumura et al.13 showed that great vessel invasion was a
significant prognostic predictor. The results of our study
and others14 did not find a significant change in the
prognosis associated with great vessel invasion. This is
perhaps due to the small number of patients involved in the
study and/or the correlation with other variables.
FIGURE 4. Kaplan-Meier curve for overall survival and recurrence-free survival of groups A and B. Group A (limited invasion
group, single organ invasion  two organs invaded, and tumor less than 6.5 cm); group B (extensive invasion group, two organs
invaded, and tumor 6.5 cm or larger   three organs invaded). Panel A (R0 resection) and panel B (R0  R1 resection).
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Therefore, the results of our study demonstrate that
completely resected stage III TENs, if there was no signifi-
cant different distributions of WHO histologic classification,
can be divided into subgroups. The patients with disease
invasion involving multiple organs and larger tumors had a
reduced likelihood of a complete surgical resection and a
poorer prognosis compared with patients with limited disease
invasion to a single organ and smaller tumors. We divided
completely resected stage III TENs into a limited disease
group and an extensive disease group. The limited disease
group had a better recurrence-free survival compared with the
extensive group. In addition, the survival curve for the limited
invasion group was more similar to the stage II thymomas
than the stage III TENs, as noted in our previous report.17
Therefore, our findings suggest that a revised staging system
for TEN that includes the number of organs involved and the
size of the TEN should be considered as proposed by
Asamura et al.18 in 2004.
In conclusion, the results of this study showed that
stage III TENs represent a broad disease spectrum of locally
advanced thymic epithelial tumors. Treatment plans, accord-
ing to these subgroups, will potentially improve patient man-
agement and survival outcomes. However, further investiga-
tions such as multicenter or multinational studies are needed
to confirm the subgroups identified and clarify the signifi-
cance of other prognostic factors in patients with stage III
TEN to improve our understanding of this disease and patient
treatment and survival.
REFERENCES
1. Loehrer PJ Sr, Jiroutek M, Aisner S, et al. Combined etoposide,
ifosfamide, and cisplatin in the treatment of patients with advanced
thymoma and thymic carcinoma: an intergroup trial. Cancer 2001;91:
2010–2015.
2. Morgenthaler TI, Brown LR, Colby TV, Harper CM Jr, Coles DT.
Thymoma. Mayo Clin Proc 1993;68:1110–1123.
3. Shimosato Y. Controversies surrounding the subclassification of thy-
moma. Cancer 1994;74:542–544.
4. Masaoka A, Monden Y, Nakahara K, Tanioka T. Follow-up study of
thymomas with special reference to their clinical stages. Cancer 1981;
48:2485–2492.
5. Blumberg D, Port JL, Weksler B, et al. Thymoma: a multivariate
analysis of factors predicting survival. Ann Thorac Surg 1995;60:908–
913; discussion 914.
6. Kondo K, Monden Y. Therapy for thymic epithelial tumors: a clinical
study of 1,320 patients from Japan. Ann Thorac Surg 2003;76:878–884;
discussion 884–885.
7. Maggi G, Casadio C, Cavallo A, Cianci R, Molinatti M, Ruffini E.
Thymoma: results of 241 operated cases. Ann Thorac Surg 1991;51:
152–156.
8. Nakahara K, Ohno K, Hashimoto J, et al. Thymoma: results with
complete resection and adjuvant postoperative irradiation in 141 con-
secutive patients. J Thorac Cardiovasc Surg 1988;95:1041–1047.
9. Quintanilla-Martinez L, Wilkins EW Jr, Choi N, Efird J, Hug E, Harris
NL. Thymoma. Histologic subclassification is an independent prognostic
factor. Cancer 1994;74:606–617.
10. Regnard JF, Magdeleinat P, Dromer C, et al. Prognostic factors and
long-term results after thymoma resection: a series of 307 patients.
J Thorac Cardiovasc Surg 1996;112:376–384.
11. Verley JM, Hollmann KH. Thymoma. A comparative study of clinical
stages, histologic features, and survival in 200 cases. Cancer 1985;55:
1074–1086.
12. Wilkins KB, Sheikh E, Green R, et al. Clinical and pathologic predictors
of survival in patients with thymoma. Ann Surg 1999;230:562–572;
discussion 572–564.
13. Okumura M, Miyoshi S, Takeuchi Y, et al. Results of surgical treatment
of thymomas with special reference to the involved organs. J Thorac
Cardiovasc Surg 1999;117:605–613.
14. Wright CD, Wain JC, Wong DR, et al. Predictors of recurrence in
thymic tumors: importance of invasion, World Health Organization
histology, and size. J Thorac Cardiovasc Surg 2005;130:1413–1421.
15. Yagi K, Hirata T, Fukuse T, et al. Surgical treatment for invasive
thymoma, especially when the superior vena cava is invaded. Ann
Thorac Surg 1996;61:521–524.
16. Rosai J. Histological typing of the thymus. In J Rosai (Ed.), World
Health Organization International Histological Classification of Tumors,
2nd Ed. Berlin: Springer-Verlag, 1999.
17. Lee HS, Kim ST, Lee J, et al. A single institutional experience of thymic
epithelial tumours over 11 years: clinical features and outcome and
implications for future management. Br J Cancer 2007;97:22–28.
18. Asamura H, Nakagawa K, Matsuno Y, Suzuki K, Watanabe S, Tsuchiya
R. Thymoma needs a new staging system. Interact Cardiovasc Thorac
Surg 2004;3:163–167.
19. Suster S, Moran CA. Thymoma classification: current status and future
trends. Am J Clin Pathol 2006;125:542–554.
20. Kim DJ, Yang WI, Choi SS, Kim KD, Chung KY. Prognostic and
clinical relevance of the World Health Organization schema for the
classification of thymic epithelial tumors: a clinicopathologic study of
108 patients and literature review. Chest 2005;127:755–761.
21. Myojin M, Choi NC, Wright CD, et al. Stage III thymoma: pattern of
failure after surgery and postoperative radiotherapy and its implication
for future study. Int J Radiat Oncol Biol Phys 2000;46:927–933.
22. Nakagawa K, Asamura H, Matsuno Y, et al. Thymoma: a clinicopath-
ologic study based on the new World Health Organization classification.
J Thorac Cardiovasc Surg 2003;126:1134–1140.
Journal of Thoracic Oncology • Volume 4, Number 12, December 2009 Prognostic Factors for Stage III Thymoma
Copyright © 2009 by the International Association for the Study of Lung Cancer 1567
